NTRB
NASDAQ HealthcareNutriband Inc. - Common Stock
Biotechnology
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
๐ Market Data
| Price | $8.13 |
|---|---|
| Volume | 109,486 |
| Market Cap | 98.83M |
| Beta | 2.040 |
| RSI (14-Day) | 87.1 Overbought |
| 200-Day MA | $4.03 |
| 50-Day MA | $4.06 |
| 52-Week High | $8.63 |
| 52-Week Low | $2.80 |
| Forward P/E | -35.35 |
| Price / Book | 18.56 |
๐ฏ Investment Strategy Scores
NTRB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (99/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (2/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NTRB in your text
Paste any article, transcript, or post โ the tool will extract NTRB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.